K. Fujita, T. Ito, K. Maruta, R. Teradaira, H. Beppu, Y. Nakacami, Y. Kato, T. Nagatsu, T. Kato

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)


Abstract— Dopamine‐β‐hydroxylase (DBH) activity in serum was decreased significantly in schizophrenic patients (16.17 ± 12.60 μmol/min/1 of serum, mean ± S.D., n = 149) when compared with that of normal controls (42.53 ± 30.94 μmol/min/1 of serum, mean ± S.D., n= 153) and neurotic patients. Long duration of disease did not cause any significant changes in serum DBH activity except a tendency for increase in patients of lodger than 18 years duration. We also examined the possibility that the serum DBH deficiency in the schizophrenic group was an artifact of treatment with antipsychotic drugs, especially phenothiazines. No significant difference was observed between the patients treated with the drugs and the patients not receiving the drugs.

Original languageEnglish
Pages (from-to)1569-1572
Number of pages4
JournalJournal of neurochemistry
Issue number6
Publication statusPublished - 06-1978

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'SERUM DOPAMINE‐β‐HYDROXYLASE IN SCHIZOPHRENIC PATIENTS'. Together they form a unique fingerprint.

Cite this